/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel trifocal IOL extends range of vision

    Early results for visual acuity, contrast sensitivity, and photopic symptoms are encouraging

    Take home message: A new non-apodized diffractive trifocal IOL allows 88% energy utilization and sends energy to near (40 cm), a preferred intermediate distance (60 cm), and far (infinity). Early results for visual acuity, contrast sensitivity, and photopic symptoms are encouraging.


    Maastricht, The Netherlands—A new non-apodized diffractive trifocal presbyopia-correcting IOL (AcrySof IQ PanOptix, Alcon Laboratories) is designed to bring patients a full and seamless range of uncorrected vision, including a wide range of comfortable near to intermediate vision (40 to 80 cm) with a crisp focal point at 60 cm.

    The new IOL was launched in Europe at the 2015 meeting of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, Spain, and is not available in the United States.It features patented optical technology (ENLIGHTEN; ENhanced LIGHT ENergy) that redistributes the extended intermediate focal point (120 cm) to the distance focal point for an amplified performance. The novel diffractive optic has two step heights, sends energy to three foci—near (40 cm), a preferred intermediate distance (60 cm) and far (infinity)—regardless of pupil size, and allows 88% energy utilization.


    At the ESCRS Congress, Rudy M.M.A. Nuijts, MD, PhD, presented positive early clinical outcomes for a small series of patients with the new trifocal IOL implanted at the University Eye Clinic Maastricht, the Netherlands.

    Dr. Nuijts and his colleagues, Soraya M.R. Jonker, MD, and Noël J.C. Bauer, MD, PhD, analyzed the outcomes and put them into perspective by comparing them with historical control groups implanted with another trifocal multifocal IOL (Fine Vision Micro F, Physiol) or a +3.0 D bifocal multifocal IOL (AcrySof IQ ReSTOR +3.0, Alcon Laboratories).

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results